Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

BACKGROUND: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown survival benefit as a switch maintenance treatment after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). The primary objective of this trial is to establish the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Rachel, Lee, Kelvin, Wallace, Paul K., Reid, Mary, Muhitch, Jason, Dozier, Askia, Mesa, Circe, Luaces, Patricia L., Santos-Morales, Orestes, Groman, Adrienne, Cedeno, Carlos, Cinquino, Aileen, Fisher, Daniel T., Puzanov, Igor, Opyrchal, Mateusz, Fountzilas, Christos, Dai, Tong, Ernstoff, Marc, Attwood, Kristopher, Hutson, Alan, Johnson, Candace, Mazorra, Zaima, Saavedra, Danay, Leon, Kalet, Lage, Agustin, Crombet, Tania, Dy, Grace K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382666/
https://www.ncbi.nlm.nih.gov/pubmed/35992783
http://dx.doi.org/10.3389/fonc.2022.958043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382666/
https://www.ncbi.nlm.nih.gov/pubmed/35992783
http://dx.doi.org/10.3389/fonc.2022.958043

Ejemplares similares